Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SterisFRA:2TG -0.20%91 EV-to-EBITDA is 15.13 as of Aug. 13, 2026, which is 19% below its 10-year median of 18.60. GuruFocus rates FRA:2TG with a GF Score™ of 91/100 and a GF Value™ of €224.68. The stock has 1 warning sign investors should review. Among 514 Medical Devices & Instruments companies, Steris ranks worse than 50.97% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Steris's enterprise value is €21,351 Mil.
Steris's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €1,411 Mil. Therefore, Steris's EV-to-EBITDA for today is 15.13.
The historical rank and industry rank for Steris's EV-to-EBITDA or its related term are showing as below:
FRA:2TG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.22 Med: 18.6 Max: 38.41
Current: 15.02
During the past 13 years, the highest EV-to-EBITDA of Steris was 38.41. The lowest was 12.22. And the median was 18.60.
FRA:2TG's EV-to-EBITDA is ranked worse than 50.97% of 514
companies
in the Medical Devices & Instruments industry
Industry Median: 14.825
vs FRA:2TG: 15.02
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2026-08-13), Steris's stock price is €197.80.
Steris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was €7.036. Therefore, Steris's PE Ratio (TTM) for today is 28.11.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Steris's share price for today is €197.80.
Steris's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €7.036.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Steris's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:2TG vs ZBH, GEHC, DXCM: EV-to-EBITDA Comparison
For the Medical Devices subindustry, Steris's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Steris EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Steris's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Steris's EV-to-EBITDA falls into.
Steris's current Enterprise Value is €21,351 Mil.
Steris's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1,411 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Steris (FRA:2TG) has a EV-to-EBITDA of 15.13 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Steris. This is 19% below median its historical median of 18.60. Over the past decade, Steris' EV-to-EBITDA has ranged from 12.22 to 38.41. According to the industry distribution chart, Steris ranks #262 out of 514 companies in the Medical Devices & Instruments industry, placing it in the top 51%.
Is Steris' EV-to-EBITDA too high?
Steris' current EV-to-EBITDA of 15.13 is 19% below median its 10-year median of 18.60. Over the past 10 years, this metric has ranged from a low of 12.22 to a high of 38.41. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.83. Steris' value of 15.13 is 2.1% above this industry median. Based on the distribution chart, Steris ranks #262 out of 514 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Steris has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Steris' EV-to-EBITDA compare to ZBH and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Steris ranks #262 out of 514 companies for EV-to-EBITDA. This places Steris in the lower half of its industry. The industry median EV-to-EBITDA is 14.83. Steris' value of 15.13 is 2.1% above this benchmark. Historically, Steris' own EV-to-EBITDA has ranged from 12.22 to 38.41 over the past decade. While the company's 10-year median is 18.60 vs. the industry median of 14.83, Steris has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.83, based on 514 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Steris's current EV-to-EBITDA of 15.13 is 2.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Steris. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Steris's current EV-to-EBITDA is 15.13, which is 19% below median its own 10-year median of 18.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Steris stock overvalued right now?
Steris (FRA:2TG) has a current EV-to-EBITDA of 15.13. The stock's GF Value™ is €224.68, compared to a current price of €197.80 — trading 12% below its estimated fair value. The current EV-to-EBITDA is 15.13, which is 19% below median its 10-year median of 18.60 and 2.1% above the Medical Devices & Instruments industry median of 14.83. Steris' overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Steris (FRA:2TG), the current EV-to-EBITDA is 15.13 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Steris (FRA:2TG) Overvalued in 2026?
Based on GuruFocus' analysis, Steris stock appears to be undervalued.
The current stock price of €197.80 is trading 12% below its estimated GF Value™ of €224.68.
Key valuation signals for FRA:2TG:
EV-to-EBITDA: 15.13 (19% below median its 10-year median of 18.60)
GF Value™: €224.68 vs. price of €197.80 (12% below fair value)
Industry Position: 2.1% above the Medical Devices & Instruments median (#262 of 514)
No single metric tells the full story. See the FRA:2TG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 20% from Applied Sterilization Technologies, or AST, and 10% from life sciences services after the divestment of its dental products business.
91GF Score
Get the complete analysis for FRA:2TG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2TG has been successfully added to your 
